2025-10-30 - Analysis Report
Okay, here's an analysis of UNH (UnitedHealth Group Inc.) based on the data you provided, presented in English with a focus on key insights and actionable takeaways:

## UNH (UnitedHealth Group Inc.) Analysis

**Company Overview:** UnitedHealth Group Inc. is a diversified healthcare company providing a wide range of healthcare products and services.

### 1. Performance vs. S&P 500 (VOO)

*   **UNH Cumulative Return:** -16.93%
*   **VOO Cumulative Return:** 104.04%
*   **Absolute Divergence:** -116.2% (UNH significantly underperforming VOO)
*   **Relative Divergence:** 9.0% (This indicates that the current divergence is near the lowest end of its historical range, suggesting UNH's underperformance is near its worst relative to the S&P 500.)

**Interpretation:** UNH has significantly underperformed the S&P 500. The low relative divergence suggests this underperformance is historically significant.

### 2. Alpha, Beta Analysis

| Year       | CAGR     | MDD      | Alpha     | Beta   | Cap(B)  |
|------------|----------|----------|-----------|--------|---------|
| 2015-2017  | 58.0%    | 66.4%    | 30.0%     | 0.1    | 199.7   |
| 2016-2018  | 41.0%    | 70.4%    | 26.0%     | 0.1    | 225.6   |
| 2017-2019  | 36.0%    | 73.8%    | 14.0%     | 0.2    | 266.2   |
| 2018-2020  | -43.0%   | 81.2%    | -67.0%    | 0.5    | 317.6   |
| 2019-2021  | 16.0%    | 81.2%    | -30.0%    | 1.5    | 454.8   |
| 2020-2022  | -1.0%    | 81.2%    | 0.0%      | 1.5    | 480.1   |
| 2021-2023  | 24.0%    | 80.8%    | 23.0%     | 0.4    | 476.8   |
| 2022-2024  | -27.0%   | 78.8%    | -47.0%    | 0.3    | 458.1   |
| 2023-2025  | -59.0%   | 78.8%    | -128.0%   | 1.2    | 325.4   |

**Interpretation:**

*   **CAGR:** Declining CAGR over the more recent periods indicates weakening growth.
*   **MDD:** Consistently high MDD indicates significant price volatility and risk.
*   **Alpha:** Negative alpha in recent periods suggests UNH is underperforming relative to its risk (beta).
*   **Beta:** Increasing beta in some periods indicates UNH's price is becoming more correlated with, and sensitive to, market movements.

### 3. Recent Price Action

*   **Current Price:** 359.325
*   **Last Market Close:** price: 359.63, previousClose: 367.84, change: -2.23
*   **5-Day Moving Average:** 361.949
*   **20-Day Moving Average:** 359.8982
*   **60-Day Moving Average:** 328.0133

**Interpretation:**

*   The price is below the 5-day and 20-day moving averages, but above the 60-day moving average. This suggests a possible short-term downtrend, but it's important to note that it still on the uptrend based on 60 day MA.
*   The significant drop in the last market close (change: -2.23) suggests some immediate negative pressure.

### 4. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (Medium to High Investment Recommendation)
*   **RSI:** 39.91 (Approaching Oversold)
*   **PPO:** -0.42 (Slightly Bearish)
*   **Hybrid Signal:** cash_79%_Sell 79.7% of holdings (243 shares - Risky - MRI:0.50) (Cash Ratio: 79% on 2025-10-16)
*   **Delta_Previous_Relative_Divergence:** -2.0 (Indicates short-term price decline)
*   **Expected Return (%):** -165.3% (Very Negative Long-Term Outlook vs. S&P 500)

**Interpretation:**

*   The RSI suggests the stock is approaching oversold territory, which *could* indicate a potential bounce.
*   The PPO indicates a slight bearish trend.
*   The hybrid signal is strongly bearish, recommending a significant reduction in holdings and a high cash position.
*   The negative expected return is a major red flag, suggesting substantial underperformance relative to the S&P 500 over the long term.

### 5. Recent News & Significant Events

*   Multiple downgrades from analysts (Investing.com, The Fly).
*   UBS and RBC adjusted price targets, but maintained "Buy" or "Outperform" ratings.
*   Reports on mixed Q3 results and adjusted EPS outlook (Zacks).

**Interpretation:** Recent news is mixed, but the downgrades are a significant concern. While some analysts maintain positive ratings, the downgrades suggest a re-evaluation of UNH's prospects.

### 6. Analyst Opinions

*   **Consensus:** "Buy" (Mean: 1.93)
*   **Target Price (avg/high/low):** 382.04 / 440.00 / 198.00

**Interpretation:** Analyst consensus remains positive overall. However, the wide range in target prices (particularly the low of $198) indicates significant uncertainty.  Pay close attention to the reasons *behind* recent rating changes.

### 7. Recent Earnings Analysis

| 날짜       | EPS   | 매출         |
|------------|-------|--------------|
| 2025-10-28 | 2.59  | 113.16 B$    |
| 2025-08-11 | 3.76  | 111.62 B$    |
| 2025-05-07 | 6.9   | 109.58 B$    |
| 2024-11-04 | 6.56  | 100.82 B$    |
| 2025-10-28 | 6.56  | 100.82 B$    |

**Interpretation:**

*   Revenue is generally trending upward, indicating growth in the company's top line.
*   EPS is volatile and the most recent EPS (2.59) is significantly lower than previous quarters.

### 8. Financial Information:

**Revenue and Profitability:**

| Quarter    | Revenue      | Profit Margin |
|------------|--------------|---------------|
| 2025-06-30 | $111.62B     | 17.93%        |
| 2025-03-31 | $109.58B     | 21.70%        |
| 2024-12-31 | $100.81B     | 21.14%        |
| 2024-09-30 | $100.82B     | 22.84%        |
| 2024-06-30 | $98.86B      | 22.31%        |

**Capital and Profitability:**

| Quarter    | Equity       | ROE     |
|------------|--------------|---------|
| 2025-06-30 | $94.72B     | 3.60%   |
| 2025-03-31 | $95.04B     | 6.62%   |
| 2024-12-31 | $92.66B     | 5.98%   |
| 2024-09-30 | $94.53B     | 6.41%   |
| 2024-06-30 | $89.36B      | 4.72%   |

**Interpretation:**

*   Revenue is increasing.
*   Profit Margin has decreased.
*   ROE has decreased, indicating the company is generating less profit from shareholders' equity.

### 9. Overall Assessment

**Summary:**

UNH exhibits several concerning trends:

*   Significant underperformance compared to the S&P 500.
*   Declining growth (CAGR) and increasing volatility (MDD).
*   Negative alpha suggests poor risk-adjusted returns.
*   Recent downgrades and mixed news sentiment.
*   Lower EPS and decreasing profit margin and ROE.
*   Bearish technical signals (Hybrid Signal, negative expected return).
*   Increased Beta during some periods

**Investment Recommendation:**

Based on the data provided, **a cautious or even bearish stance on UNH appears warranted.** The negative long-term outlook, the significant underperformance, and the recent downgrades raise red flags.

**Caveats:**

*   Analyst consensus remains "Buy," but the reasons behind the downgrades should be investigated.
*   The RSI suggests the stock may be oversold, so a short-term bounce is possible.

**Further Research:**

*   Deep dive into the reasons for the EPS decline and downgrades.
*   Assess the impact of potential healthcare policy changes on UNH's business.
*   Monitor technical indicators closely for signs of a trend reversal.

**Disclaimer:** This analysis is based solely on the provided data and does not constitute financial advice.  Consult with a qualified financial advisor before making any investment decisions.
